Prolonged Hyperglycemia Reduces Elasticity of Type II Diabetic Rat Bone.

An increase in bone fracture risk has been reported in patients with diabetes. To evaluate an early effect of glucose intolerance on bone homeostasis, we have characterized bones from spontaneously diabetic torii (SDT) rats, an animal model of type 2 diabetes in comparison with Sprague Dawley (SD) rats as healthy control. Focusing on early effects of diabetes on bone elasticity, longitudinal wave velocities of animal bones were first determined by a micro-Brillouin scattering technique in a non-destructive way. Wave velocities in the cortical and cancellous bones in the tibias of the SDT and SD rats were compared. In a pre-diabetic stage at approximately 10 weeks of age, there seems no significant difference in wave velocities in bones from age-matched SDT and SD rats. By contrast, after the onset of diabetes at approximately 20 weeks of age, the mean velocities of bones from SDT rats were lower than those of SD rat. In addition, the X-ray CT showed that the bone amounts of SDT rats were smaller than those of SD rats in an early diabetic stage at 20 weeks of age. The current study demonstrated that the wave velocity decreased in bones of SDT rats in the early stages of diabetes. While a decrease of bone strength in an early stage of diabetes can be partially explained from decreases in bone amount as well as bone elasticity, further studies will be needed in understanding a detailed mechanism of bone deterioration due to diabetes.

Visualization of Amyloid ß Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry.

The neuropathology of Alzheimer's disease (AD) is characterized by the accumulation and aggregation of amyloid ß (Aß) peptides into extracellular plaques of the brain. The Aß peptides, composed of 40 amino acids, are generated from amyloid precursor proteins (APP) by ß- and γ-secretases. Aß is deposited not only in cerebral parenchyma but also in leptomeningeal and cerebral vessel walls, known as cerebral amyloid angiopathy (CAA). While a variety of Aß peptides were identified, the detailed production and distribution of individual Aß peptides in pathological tissues of AD and CAA have not been fully addressed. Here, we develop a protocol of matrix-assisted laser desorption/ionization-based imaging mass spectrometry (MALDI-IMS) on human autopsy brain tissues to obtain comprehensive protein mapping. For this purpose, human cortical specimens were obtained from the Brain Bank at the Tokyo Metropolitan Institute of Gerontology. Frozen cryosections are cut and transferred to indium-tin-oxide (ITO)-coated glass slides. Spectra are acquired using the MALDI system with a spatial resolution up to 20 µm. Sinapinic acid (SA) is uniformly deposited on the slide using either an automatic or a manual sprayer. With the current technical advantages of MALDI-IMS, a typical data set of various Aß species within the same sections of human autopsied brains can be obtained without specific probes. Furthermore, high-resolution (20 µm) imaging of an AD brain and severe CAA sample clearly shows that Aß1-36 to Aß1-41 were deposited into leptomeningeal vessels, while Aß1-42 and Aß1-43 were deposited in cerebral parenchyma as senile plaque (SP). It is feasible to adopt MALDI-IMS as a standard approach in combination with clinical, genetic, and pathological observations in understanding the pathology of AD, CAA, and other neurological diseases based on the current strategy.

Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models.

Selenoprotein P (SeP) functions as a selenium (Se)-supply protein. SeP is identified as a hepatokine, promoting insulin resistance in type 2 diabetes. Thus, the suppression of Se-supply activity of SeP might improve glucose metabolism. Here, we develop an anti-human SeP monoclonal antibody AE2 as with neutralizing activity against SeP. Administration of AE2 to mice significantly improves glucose intolerance and insulin resistance that are induced by human SeP administration. Furthermore, excess SeP administration significantly decreases pancreas insulin levels and high glucose-induced insulin secretion, which are improved by AE2 administration. Epitope mapping reveals that AE2 recognizes a region of human SeP adjacent to the first histidine-rich region (FHR). A polyclonal antibody against the mouse SeP FHR improves glucose intolerance and insulin secretion in a mouse model of diabetes. This report describes a novel molecular strategy for the development of type 2 diabetes therapeutics targeting SeP.